The emergence of evidence has revealed that TRPM2, a highly Ca2+ permeable cation channel, acts as a regulator in cancer growth and survival, and is correlated with poor prognosis in patients with breast, gastric, pancreatic, prostate, head and neck cancers, melanoma, and neuroblastoma. This evidence concerns the gene TRPM2 and cancer.